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Background: Depression can be treated in an outpatient, inpatient or day hospital setting. In the German health
care system, episodes of inpatient or day hospital treatment are common, but there is a lack of studies evaluating
effectiveness in routine care and subgroups of patients with a good or insufficient treatment response. Our study
aims at identifying prognostic and prescriptive outcome predictors as well as comparative effectiveness in
psychosomatic inpatient and day hospital treatment in depression.
Methods/Design: In a naturalistic study, 300 consecutive inpatient and 300 day hospital treatment episodes in
seven psychosomatic hospitals in Germany will be included. Patients are assessed at four time points of
measurement (admission, discharge, 3-months follow-up, 12-months follow-up) including a broad range of variables
(self-report and expert ratings). First, the whole sample will be analysed to identify prognostic and prescriptive
predictors of outcome (primary outcome criterion: Quick Inventory of Depressive Symptoms QIDS-total score,
expert rating). Secondly, for a comparison of inpatient and day hospital treatment, samples will be matched
according to known predictors of outcome.
Discussion: Naturalistic studies with good external validity are needed to assess treatment outcome in depression
in routine care and to identify subgroups of patients with different therapeutic needs.
Trial registration: Current Controlled Trials ISRCTN20317064
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Depression is one of the most common diseases with a life
time prevalence rate of 17.1% and a 12-months prevalence
of 10.7% [1]. It is a leading cause of disability worldwide
[2]. The German health care system provides outpatient,
inpatient and day hospital care for depression [3]. Two
medical specialties are involved in the treatment of mental
disorders: psychiatry and psychosomatic medicine. Psy-
chosomatic inpatient and day hospital treatment programs
are characterized by a stronger focus on psychotherapy as
the main treatment modality, integrating psychopharma-
cological and somatic treatment elements. About 40-50%
of the patients treated in psychosomatic hospitals have a* Correspondence: almut.zeeck@uniklinik-freiburg.de
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reproduction in any medium, provided the ormain diagnosis of major depression [4-6]. In contrast to
many other countries, inpatient treatment plays an im-
portant role: ~64.500 beds are provided in psychiatric and
~6400 in psychosomatic hospitals for acute care, with an
additional 15.400 beds in psychosomatic rehabilitation
hospitals, covering a considerable part of health care for
people with mental diseases.
In comparison to outpatient treatment, hospital pro-
grams have the advantage of using a multimodal approach,
combining daily structure with individual, group and add-
itional treatment components [5]. Day hospital programs
for acute psychosomatic care are comparable to inpatient
programs with the difference that patients return home at
evenings and weekends. There is an increasing interest in
day hospital programs, because of the lower costs of this
treatment modality [7,8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in psychosomatic medicine as well as in psychiatry, there
is a lack of studies on inpatient or day hospital treatment.
Additionally, previous studies do not take into account
the marked heterogeneity of patients with this diagnosis:
Depression in one subject is not like depression in another
(“uniformity myth”; [9]). This will be especially true for
the patient group treated in inpatient and day clinic units,
who show high rates of co-morbidity with mental or som-
atic disorders, a severe course of the illness or complex
problems including the social and family situation. It can
be postulated that tailoring treatments to the needs of
subgroups of patients with special characteristics will im-
prove overall outcome, which is reported to lie around a
mean value of 30-40% remission rates after “standard
treatment” for depression [3].
There are few naturalistic studies describing effects of
psychosomatic inpatient and day hospital treatment,
mostly lacking follow-up assessments and a detailed
description of patients characteristics (personality, co-
morbidity) [4-6,10-12]. The majority of studies report
on heterogeneous samples including depressed patients
besides other diagnoses. There is no study trying to
identify subgroups of patients with a main diagnosis of
major depression with different symptom courses and
no study comparing inpatient and day hospital treat-
ment. The same is true for psychiatry, with a limited num-
ber of studies on this topic conducted in the German
health care system (see for example: [13-15]).
The following predictors were repeatedly found to be
associated with the course and overall outcome in depres-
sion: (1) number of episodes of major depression (MDE),
(2) duration of the current MDE, (3) co-morbidity (men-
tal, somatic) and (4) incomplete remission of the last
episode of MDE or “double depression” [3]. A higher
probability for a relapse is associated with younger age,
female gender, a lack of social support and being single.
An additional somatic illness and a late onset of treatment
are able to nearly completely explain prognosis in a higher
age group [16]. Traumatic childhood experiences were
also identified as a risk factor for depression and import-
ant to consider in terms of the long term course and risk
for relapse [17]. Most of these factors have been found in
studies on outpatient treatment for depression. It remains
unclear, if the same predictors will be identified analysing
samples of patients treated within an inpatient or day hos-
pital setting.
Another group of studies focusses on the influence of
personality characteristics on the course and prognosis
of depression. One of the most relevant concepts in this
field is the one of Sydney Blatt, who postulated a two-
dimensional model, which differentiates between depressed
patients who primarily deal with problems in interpersonal
relatedness (“anaclitic”: fears of abandonment; dependency)and those preoccupied with self-definitional issues (“intro-
jective”: hash self-criticism; perfectionism) [18]. There is an
ongoing debate on the relevance of this theoretic modela.
In support of it, perfectionism as a trait was repeatedly
found to be associated with a more problematic course in
depression. Overall, it can be assumed that personality
traits and other patient variables (social support, interper-
sonal problems, etc.) are not only overall predictors of
outcome, but also interact with the form of treatment or
setting provided.
Studies comparing inpatient and day hospital treat-
ment found comparable outcomes for patients with
mental disorders, for whom both settings are suitable
[8]. We could replicate this finding for a psychosomatic
clinic in Germany [11], but found differences in effects
when analysing outcome for single diagnostic categories
like eating disorders [19,20]. Comparing means of large
samples might cover differences between subgroups,
which can be better treated in one or the other setting.
In a pilot study, we tried to identify predictors of differ-
ential outcome of inpatient and day hospital treatment
and found a higher motivation for psychotherapy and
higher burdens at home to be associated with a good
outcome after day hospital treatment, whereas strong
wishes to give up responsibility for oneself were associ-
ated with an unfavourable course of inpatient treatment
[5,21]. Strong wishes to give up responsibility might be
associated with “anaclitic” features according to S. Blatt
et al. [18], but this has to be shown empirically.
The INDDEP (Inpatient and Day Hospital Treatment
for Depression) - study is a naturalistic study which aims
at the description and comparison of symptom courses
after psychosomatic inpatient and day hospital treatment
for major depression. It further aims at identifying “prog-
nostic” (associated with general outcome) and “prescrip-
tive” (associated with the differential outcome in both
settings) variables, which can help to discriminate sub-
groups of patients with differences in course and treat-
ment needs [22]. Finally, we aim to go beyond previous
studies in assessing not only socio-demographic variables
and aspects of depressive symptomatology, but also per-
sonality traits, coping style and interpersonal problems as
possibly relevant predictors.
Methods
For to analyse a sample which represents the clinical real-
ity of psychosomatic inpatient and day hospital treatment
for depression in Germany (external validity), we did not
choose a randomized design as we expected only a minor-
ity of patients to agree to a randomization procedure and
expected considerable resistance in non-university centres.
Therefore, the study is naturalistic in nature and com-
poses two steps: I) an analysis of predictors in the whole
sample and II) a comparison of inpatient and day clinic
Table 1 Inclusion and exclusion criteria of the INDDEP-
study
Inclusion criteria • MDE (major depressive episode, unipolar,
according to DSM IV) as main diagnosis
• age 18-65
• QIDS-C score > 10
• informed consent
• sufficient knowledge of German language
Exclusion criteria • psychotic disorder (current or life time)
• bipolar disorder
• substance dependency (current or last
three years)
• current suicidal ideation
• antisocial personality disorder
• cognitive impairment, dementia
• admission for diagnostic reasons
(not for treatment)
• second admission during recruitment period
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son of inpatient and day clinic treatment, samples will be
parallelized according to known predictors of outcome
(see: methods against bias).
Study centers
The study is carried out at 7 German study sites. These
comprise three psychosomatic departments at university
hospitals and four clinics outside the university context.
All departments or clinics provide a treatment program
that is typical for clinics of psychosomatic medicine in
Germany (see [5,21]). Participating centers are the De-
partment of Psychosomatic Medicine and Psychotherapy
at the University Clinic of Freiburg, the Clinic of Psycho-
somatic Medicine and Psychotherapy at the University
of Ulm, the Department of Psychosomatic Medicine and
Psychotherapy at the University Clinic of Mainz, the
Clinic for Psychosomatic Medicine and Psychotherapy at
the Robert-Bosch-Krankenhaus Stuttgart, the Thure-von
Uexküll-Klinik Freiburg, the Clinic for Psychosomatic
Medicine and Psychotherapy at the Bürgerhospital in
Stuttgart and the Rhein-Klinik, Bad Honnef.
Participants
During a 2.5-year recruitment period, all patients admit-
ted to the participating clinics will be screened for de-
pressive symptoms and inclusion and exclusion criteria
checked. Recruitment will be continued until a sample
of 300 patients is reached in each setting (inpatient, day
hospital). There has to be a minimum of 35 patients per
setting in each centre to control for centre effects. Re-
search assistants will be involved, if a depression can be
identified as the main reason for admission or the most
dominant problem (main diagnosis). The research assist-
ant will inform the patient about the study and check in-
clusion and exclusion criteria. Inclusion and exclusion
criteria are listed in Table 1. Patients will get compre-
hensive information about the study and are included
after written consent. There is permission from the local
ethics committees.
Interventions
Interventions comprise the routinely provided inpatient
and day hospital treatment programs of psychosomatic
clinics in Germany. These include individual and group
psychotherapy, art and body therapy, relaxation therapy,
family sessions and support of a social worker if needed,
psychopharmacology, educational elements, physician
rounds and medical care (see [5]). Treatment duration
usually comprises between 4 and 12 weeks [5].
Measurement time points
Time points of measurement will be the time point at ad-
mission (T0), at discharge (T1), a three months follow-up(T2) and a 12 months follow-up (T3). Data will include a
detailed assessment on different levels: symptomatology
(characteristics of depression and co-morbid conditions),
general disturbance and quality of life, aspects of personal-
ity, interpersonal problems and a further aspects that has
been identified to influence the course of depression: trau-
matic childhood experiences. Variables will be grouped
into classes of possible predictors. A combination of self-
report and assessments by independent, trained research
assistants will be used (see Table 2).
Objectives and hypotheses
First, the study aims to describe changes in depressive
symptomatology during and after psychosomatic inpatient
and day hospital treatment for depression and to identify
subgroups with a good or less favourable symptom course
(observational) including follow-up assessments.
Secondly, inpatient and day clinic treatment will be
compared (matched samples). It is assumed that type of
depression according to S. Blatt (introjective/high level
of perfectionism vs. anaclitic/high level for dependency)
is associated with differential outcome in each setting.
Outcomes
The Quick Inventory of Depressive Symptomatology
QIDS-C (expert rating) is chosen as the main outcome
criterion. The QIDS is a 16-item version of the Inventory
of Depressive Symptomatology (IDS), which shows high
correlations with other instruments for the measurement
of depressive symptomatology [23]. It´s a common, inter-
nationally used, licence-free instrument which has a self-
report and an expert rating form [23]. The QIDS was
chosen as its total score is also used as the main outcome
Table 2 Instruments used the INDDEP study
Time point of measurement Outcome/Variables Patient Research assistant
(self-report) (expert rating)
T0 (admission) Depressive symptomatology: QIDS-SR QIDS-C, SKID-I




Overall disturbance and functioning: SCL-90-R SOFAS
Social support: F-SozU K-14
Quality of Life: SF-12
Traumatisation: CTQ
T1 (discharge) QIDS-SR QIDS-C
SCL-90-R SOFAS
IIP-32






QIDS-SR = Quick Inventory of Depressive Symptoms, self-report form [23], QIDS-C = expert rating; SCID-I and SCID-II=Structured Clinical Interview for DSM IV axis I
and II [24,25]; SCL-90-R = Symptom-Check-List 90-R [26]; DAS = Dysfunctional Attitudes Scale [27,28]; DEQ = Depressive Experiences Questionnaire [29,30];
SOFAS = Social and Occupational Functioning Assessment Scale [31]; IIP-32 = Inventory of Interpersonal Problems, 32-item version [32,33]; F-SozU K-14 =
Fragebogen zur sozialen Unterstützung, 14-item version [34]; SF-12 = Fragebogen zum Gesundheitszustand (quality of life) [35]; CTQ = Childhood Trauma
Questionnaire [36,37]; LIFE-Interview = Longitudinal Interval Follow-up Evaluation [38].
Note: Additionally assessed at all time points of measurement: pharmacological treatment, somatic diagnoses; at T0: previous treatment for depression; at
T1: documentation of treatment received (dose, components); T2 and T3: further outpatient treatment, days of sick leave, number of contacts to health
care system.
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chronic depression that is currently conducted in Germany
(“LAC-study”, [39]).
We aim to assess outcome dimensionally (change on the
QIDS-C score from admission to the three-months follow-
up) as well as categorically: a symptom reduction < 20% is
defined as “no effect”, a symptom reduction between 20%
and 50% as modest change, a symptom reduction of > 50%
as partial remission and a symptom reduction of 100% as
complete remission (falling below the cut-off value of de-
pression of the QIDS-C) [3,40].
Sample size calculation
The power calculation is based on assumptions about dif-
ferences in the frequencies of remissions by treatment set-
ting, the difference of means on the outcome measure,
attrition and loss of cases due to mismatches. Given the
probability of remission was p=0.30 for treatment A and
p=0.45 for treatment B, then for equal N in each group, α =
.05 and (1-β) = 0.80, the required sample size is N =180
(each group; calculated with PASS2008). For a standardized
difference of d = 0.2 (small effect size) and α = .05 and
(1-β) = 0.80, the required sample size is N = 200. With an
attrition rate of 10% and loss due to mismatches of 20%
(matching samples for research question II), the total sam-
ple size should be increased to N = 300 per group.Including covariates, subgroups and nesting (HLM) will
help to increase the precision of models.
Methods against bias
To compare inpatient and day clinic samples, a para-
llelization according to known predictors of outcome [14]
will be conducted: (1) Gender [m;f], (2) age [<40; >=40:
mean age in previous studies], (3) number of additional
axis-I diagnoses [<2; >=2], (4) number of previous episodes
of major depression [0; <=2; >2] and (5) duration of the
recent episode of MDE [<6 months; 6–24 mo >24 mo].
Criteria (1) to (3) will be matched 1:1; criteria (4) & (5) are
used as lenient criteria, to be matched 1:1 if possible, other-
wise the extremes may not be matched together. We ex-
pect a loss of about 20% due to “mismatches”, missing data
and patients dropping out of the study.
Antidepressant medication, the initial score of the
QIDS-C and the number of psychotherapy sessions fol-
lowing discharge will be controlled for in the final ana-
lysis. At the end of the study, patients screened and not
taking part and patients taking part in the study will be
compared, as well as patients dropping out of the study
with those completing the study.
Statistical analysis
The statistical analysis will follow the example of Fournier
et al. [22]. The continuous outcome (QIDS-C) will be
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random effects). The difference (T0-T2) will be controlled
for baseline (T0) severity. Moderator and mediator ana-
lyses will be conducted according to Kraemer et al. [41].
The analysis of categorical outcome (remission classes)
will be conducted with categorical regression with
methods of optimal scaling (SPSS-CatReg) [42]. The iden-
tification of predictors with SPSS-CatReg is based on
boot-strapping procedures or on the “Least Absolute
Shrinkage and Selection Operators” [42]. For the HLM we
will adapt the example of Fournier et al. [22] restricting
the degrees of freedom of the selection of predictors in a
hierarchical process.
Safety aspects and medical complications
There is a pseudonymisation of the data. At the end of
the study, the data per centre will be made available to
the participating centres who will remain owners of their
own data sets. The coordinating centre (Freiburg) is
responsible for data integrity and monitoring. Selected
adverse events (like suicide attempts, transfer to other
departments because of somatic problems or suicidal
ideation) are defined in the study protocol, monitored
and followed up constantly throughout the study and
documented accordingly by the investigator including
evaluation. Serious adverse events and other safety issues
that might materially alter the current risk-benefit as-
sessment should be reported by the coordinating investi-
gator (A.Z., Freiburg) and to the responsible ethics
committee according to the study protocol. As all pa-
tients get the usual standard treatment of routine care
(observational study), criteria for ending the study be-
cause of adverse events are not applicable.
Ethical issues
The final study protocol and the final version of the
written informed consent form were approved by the
ethics committee of the University of Freiburg as well as
the local ethics committees. The trial will be carried out
according to legal and regulatory requirements, the prin-
ciples of good clinical practice and according to the Dec-
laration of Helsinki.
Discussion
The INDDEP study is a naturalistic study, which aims at
the description of symptom courses in patients with de-
pression receiving inpatient or day hospital treatment in
psychosomatic clinics in Germany and the identification
of subgroups by analyzing prognostic and prescriptive var-
iables. Secondly, it aims at comparing effects of inpatient
and day clinic treatment using a quasi-experimental de-
sign (matched samples).
A naturalistic design and broad inclusion criteria were
chosen to achieve high external validity of data and todescribe treatment and symptom courses in routine care.
A randomized trial comparing inpatient treatment with
outpatient or day clinic treatment would have led to a
highly selective sample of patients having no treatment
preference. It would have resulted in data on efficacy of
treatments, but only in a small subsample. For a compari-
son of settings we choose to use the next best design:
Inpatient and day hospital samples will be parallelized
according to known predictors of outcome [14]. In the
power calculation we took into consideration that sample
size will be reduced by this procedure.
The INDDEP study is the largest study on inpatient and
day clinic treatment in depression in the German health
care system. In comparison to previous studies, it has the
advantage that patients are diagnosed by structured inter-
views and followed up 3 and twelve months after discharge
by self and expert assessments. Measurement is not limited
to symptom change only, but comprises the evaluation
on different levels relevant for overall functioning and
quality of life: socio-demographic data, co-morbidity (men-
tal, somatic), personality, coping strategies, interpersonal
problems, traumatization and social support. Additionally,
there will be a comprehensive documentation of the uti-
lization of health care services after discharge, as well as a
documentation of days of work absenteeism allowing an
economic analysis.
To study inpatient and day hospital treatments can be seen
as a problematic task, as treatments consist of multiple
therapeutic elements, are provided by different treatment
teams and hospitals are embedded in different environments.
We can only try to reduce bias as good as possible. To con-
trol for centre effects, each hospital has to recruit a mini-
mum of 35 patients in each setting. Treatment components
will be documented in detail (sort, duration, frequency), al-
though in a pilot study we found treatment programs to be
quite comparable in dose and composition of elements, due
to German standards for psychosomatic clinic programs. We
will take the nesting of data (settings, clinics) into consider-
ation by using complex statistic methodology. But we cannot
rule out that the fact of taking part in a study influences
treatment course and has some sort of impact.
In terms of dropping out of the study, we expect rates
to be low, as there are much more advantages for agree-
ment to participate compared to a refusal: Patients will
get in-depth diagnostic assessments and allowances for
filling in the questionnaires or taking part in follow-up
assessments (20€ for each time point of measurement).
Furthermore, depressed patients usually are a group of
patients with a comparably high compliance rate.
The principal investigators and participating centers are
experienced in the conduction of studies and all hospitals
provide the usual standard care of psychosomatic centres.
Most of the hospitals have been involved in the preceding
pilot study [5,21].
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on the treatment of depression in the German health care
system and help to tailor treatment programs to the needs
of different subgroups of patients.Endnotes
aSee for example: Psychotherapy Research, volume 20,
number 1st of January 2010.Abbreviations
HLM: Hierarchical linear models; MDE: Major depressive episode; QIDS: Quick
Inventory of Depressive Symptoms.
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